Vectus Biosystems (VBS) Stock Price, News & Analysis

Company Overview

Medical research and development. Phase I human trials for anti-fibrotic drug VB0004 completed.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$4.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:VBS
• CIK: N/A
• Web: www.vectusbiosystems.com.au
• Phone: 61 2 9662 4144
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$2.34 million
• Net Margins: -205.34%
• Pretax Margin: N/A
• Return on Equity: -121.28%
• Return on Assets: -43.75%

Debt

• Debt-to-Equity Ratio: 1.95
• Current Ratio: 3.45
• Quick Ratio: 0.49

Sales & Book Value

• Annual Sales: A$1.14 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.03 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,250,000
• Free Float: N/A
• Market Cap: A$4.15 million
• Optionable: Not Optionable
• Beta: 0.87